Control Bionics Secures First U.S. LOI for iOS Speech Device Program

The latest update is out from Control Bionics Ltd. ( (AU:CBL) ).

Control Bionics has signed its first U.S. Letter of Intent for an iOS-based speech generating device program, stemming from its recent partnership with NextLevel. The non-binding agreement with a U.S. customer signals planned annual purchases of devices expected to generate between US$2.5 million and US$3.5 million in revenue once commercial supply begins toward the end of FY26, subject to final agreements and operational readiness.

As part of the arrangement, the customer will make a US$100,000 advance payment, to be credited against the first 1,000 devices supplied under the program. The deal marks the first commercial validation of Control Bionics’ strategy to expand into Apple iOS-based speech devices for the U.S. market, underscoring growing demand for tablet-based communication solutions and supporting the company’s continued investment in this segment.

The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.

More about Control Bionics Ltd.

Control Bionics Limited is an Australian neurotechnology medical device company specialising in assistive communication solutions that use surface electromyography to translate muscle signals into digital inputs. Its core NeuroNode and emerging NeuroStrip wearable technologies support speech generation, computer control and potential applications in diagnostics, sports performance and rehabilitation across markets in North America, Australia, Europe and Japan.

Average Trading Volume: 322,896

Technical Sentiment Signal: Hold

Current Market Cap: A$23.48M

For detailed information about CBL stock, go to TipRanks’ Stock Analysis page.